Etentamig

4 trials 3 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

1 Sponsors

15 Countries

Phase III

Phase II/III

Phase I/II

Phase III: 1 Phase II/III: 1 Phase I/II: 2

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 4

All trials

4 total

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-… Recruiting

2024-515770-27-00 Phase I/II 1 country AbbVie Deutschland GmbH & Co. KG
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum… Recruiting

2025-520897-21-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Recruiting

2024-512146-41-00 Phase I/II 3 countries AbbVie Deutschland GmbH & Co. KG
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Phase III 13 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–4 of 4 trials

← All drugs A–Z